Objective: The purpose of this study is to evaluate obstetric outcomes in pregnant women who received second-generation long-acting injectable antipsychotics (LAIAs) compared to a control group who received second-generation oral antipsychotics.

Methods: This was a retrospective study utilizing a global cohort of 148 health care organizations grouped into a network within the TriNetX database. Pregnant patients of any trimester were grouped into 2 cohorts: (1) exposure to long-acting aripiprazole, risperidone, paliperidone, or olanzapine (n=2,082) and (2) exposure to the corresponding oral formulations (n=31,376) and propensity matched. The primary outcome was the occurrence of one of the following obstetric complications: gestational diabetes, preeclampsia, eclampsia, or a newly diagnosed hypertensive disorder. Cesarean section rates were also assessed.

Results: After propensity matching, each cohort yielded 2,025 patients. No intergroup differences were observed in the composite primary end point, performed postmatching (odds ratio 0.95; 95% CI, 0.76–1.18; P=.61). No difference in rates of cesarean section was observed.

Conclusion: Similar rates of gestational diabetes, eclampsia, preeclampsia, and maternal hypertensive disorders were observed in women receiving long-acting injectable and oral second-generation antipsychotics.

J Clin Psychiatry 2026;87(1):25m16033

Author affiliations are listed at the end of this article.

This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you’re already a subscriber, please log in below to continue reading.